Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 4/20 | 0.46 |
| ▸ | CA2 | P00918 | 4/20 | 0.46 |
| ▸ | CA12 | O43570 | 3/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | OGA | O60502 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MMP12 | P39900 | 1/20 | 0.33 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.33 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.33 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7215110 | 1.00 | CA9 (0.46) | CA9CA2CA12CA1OGA | |
| SCHEMBL3238675 | 1.00 | CA9 (0.46) | CA9CA2CA12CA1OGA | |
| SCHEMBL12651757 | 0.98 | CA9 (0.49) | CA9CA2CA12CA1OGA | |
| SCHEMBL22227447 | 0.98 | CA9 (0.49) | CA9CA2CA12CA1OGA | |
| SCHEMBL8153537 | 0.98 | CA9 (0.49) | CA9CA2CA12CA1OGA | |
| SCHEMBL7642475 | 0.98 | CA9 (0.49) | CA9CA2CA12CA1OGA | |
| SCHEMBL7148616 | 0.98 | CA9 (0.49) | CA9CA2CA12CA1OGA | |
| SCHEMBL21575613 | 0.98 | CA9 (0.49) | CA9CA2CA12CA1OGA | |
| SCHEMBL8152918 | 0.98 | CA9 (0.49) | CA9CA2CA12CA1OGA | |
| SCHEMBL7152382 | 0.98 | CA9 (0.49) | CA9CA2CA12CA1OGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394935-B2 | Method for producing furanose derivative | API CORPORATION (JP) | 2013-03-12 | — | — | US | disclosed |
| US-20100298550-A1 | PROCESS FOR PRODUCTION OF RIBOFURANOSE DERIVATIVES | API CORPORATION (JP) | 2010-11-25 | — | — | US | disclosed |
| EP-2210896-A1 | PROCESS FOR PRODUCTION OF RIBOFURANOSE DERIVATIVES | API Corporation (JP) | 2010-07-28 | — | — | EP | disclosed |
| US-20100105890-A1 | METHOD FOR PRODUCING FURANOSE DERIVATIVE | API CORPORATION (JP) | 2010-04-29 | — | — | US | disclosed |
| EP-2105445-A1 | METHOD FOR PRODUCTION OF FURANOSE DERIVATIVE | API Corporation (JP) | 2009-09-30 | — | — | EP | disclosed |
| US-6617315-B1 | Sugar-substituted benzimidazole derivatives are used for the treatment or prophylaxis of restenosis, particularly following angioplasty | CHAMBERLAIN STANLEY DAWES (US) | 2003-09-09 | — | — | US | disclosed |
| US-6204249-B1 | L-benzimidazole nucleosides | GLAXO WELLCOME INC. | 2001-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298550-A1 | PROCESS FOR PRODUCTION OF RIBOFURANOSE DERIVATIVES | RNASEL, RPIA, RIOX2 | CA9 2740/4885CA2 2246/4885CA12 2481/4885 |
| US-20100105890-A1 | METHOD FOR PRODUCING FURANOSE DERIVATIVE | DERA, ALDOA, DPYD | CA9 793/4885CA2 1005/4885CA12 1111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.